KNSA — Kiniksa Pharmaceuticals Ltd
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$79.28
+$0.65 (+0.83%)
Kiniksa Pharmaceuticals Ltd (KNSA) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Sanj K. Patel, based in 105 Piccadilly, London, United Kingdom, W1J 7NJ, with about 366 employees. Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Latest reported KNSA revenue for 2025-09-30 was $180.9M. Net income was $44.8M. Revenue was up 15.3% from 2025-06-30 to 2025-09-30. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
Use this KNSA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the KNSA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the KNSA SEC filings page. Lician reads the product cache first so this HTML stays unique to Kiniksa Pharmaceuticals Ltd even when a live quote feed is slow.
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
KNSA Key Statistics
Market Cap
$3.73B
Volume
49,808
Previous Close
$79.38
Day Range
$79.36 – $79.85
P/E Ratio
53.21
EPS
-$0.60
Revenue
$423.24M
Net Income
-$43.19M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+56.6%
Profit Margin
-10.2%
Employees
366
KNSA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $423.24M | $270.26M | $220.18M | $38.54M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$43.19M | $14.08M | $183.36M | -$157.92M |
| EPS (Diluted) | -$0.60 | $0.20 | $2.60 | -$2.30 |
Total Assets
$580.55M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$183.58M
Operating Cash Flow
$25.69M
Free Cash Flow
$0.00
Kiniksa Pharmaceuticals Ltd Company Information
- CEO & Chairman of the Board
- Sanj K. Patel
- Headquarters
- 105 Piccadilly, London, United Kingdom, W1J 7NJ
- Website
- www.kiniksa.com
- Phone
- 44 78 1431 9100
- IPO / Founded
- 2018-05-24
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic